{"id":148850,"date":"2026-08-19T18:10:11","date_gmt":"2026-08-19T18:10:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/148850\/"},"modified":"2026-08-19T18:10:11","modified_gmt":"2026-08-19T18:10:11","slug":"novo-nordisk-cpsenovo-b-stock-still-looks-undervalued-after-dutch-court-win","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/148850\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Stock Still Looks Undervalued After Dutch Court Win"},"content":{"rendered":"\n

Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE. <\/p>\n

Novo Nordisk stock has fallen sharply over the past three years, yet the broader valuation checks still flag it as looking cheap rather than stretched. Recent headlines around obesity treatments, intellectual property protection and a large buyback programme add extra context to whether that discount is justified. <\/p>\n

The share price has declined 49.9% over the past three years, which suggests many investors have already reset their expectations for the stock. <\/p>\n

Growth expectations around GLP-1 obesity and diabetes treatments and the support from an ongoing DKK 15b share repurchase programme can help sentiment, while rising competition from Eli Lilly and pricing pressure from wider access programs may limit how much investors are willing to pay. <\/p>\n

The company screens as undervalued in 5 of 6 valuation checks<\/a>. This means the broad set of metrics leans toward the stock being on the cheap side rather than richly priced. <\/p>\n

The issue now is whether that apparent discount is a genuine opportunity or a reflection of the risks that recent returns and competitive pressures already signal. <\/p>\n

Novo Nordisk delivered -9.2% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.<\/a> <\/p>\n

Is Novo Nordisk Still Cheap on Earnings? <\/p>\n

P\/E is a useful check for Novo Nordisk because earnings remain a key focus for how investors value established pharmaceutical companies. On this measure, Novo Nordisk trades on a P\/E of 11.4x, which is noticeably lower than the Pharmaceuticals industry average of 21.7x and the peer group average of 24.2x. That gap suggests the market is currently paying much less for each krone of Novo Nordisk earnings than for many sector peers. <\/p>\n

The tailored fair P\/E ratio for Novo Nordisk is 24.4x, which reflects what investors might typically pay given its size, margins, industry and risk profile. Compared with the current 11.4x multiple, the stock trades at a sizeable discount to this fair ratio. Despite recent headlines on stronger competition from Eli Lilly in obesity drugs and pricing pressure from wider access programs such as Amazon Pharmacy’s Medicare offering, the P\/E still points to Novo Nordisk being priced more cautiously than both peers and the model benchmark. <\/p>\n

On the P\/E multiple alone, Novo Nordisk stock currently appears undervalued relative to both its industry and its own fair ratio. <\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B P\/E Ratio as at Aug 2026 <\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

Story Continues <\/p>\n

The Novo Nordisk Narrative: What Would Justify Today’s Price? <\/p>\n

Simply Wall St Narratives pick up where the Novo Nordisk valuation puzzle leaves off. They spell out which assumptions about Novo Nordisk’s future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today’s price. Each Narrative links a specific fair value estimate to a clear story about Novo Nordisk’s potential catalysts and risks, so you can track over time which version of events appears to be taking shape on the Community page. <\/p>\n

The Novo Nordisk community is split between those who see a wide valuation gap and those who think recent weakness already reflects key hurdles. <\/p>\n

Bull case: 65% undervalued <\/p>\n

“With high barriers to entry, a booming market for obesity treatment, and a pipeline that keeps expanding, Novo Nordisk’s future looks remarkably secure\u2026” <\/p>\n

Read the full Bull Case<\/a> to see why Novo Nordisk could be undervalued<\/a> <\/p>\n

Bear case: roughly fairly valued <\/p>\n

“Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand\u2026” <\/p>\n

Read the full Bear Case<\/a> to see why Novo Nordisk could be overvalued<\/a> <\/p>\n

Do you think there’s more to the story for Novo Nordisk? Head over to our Community to see what others are saying!<\/a> <\/p>\n

The Bottom Line <\/p>\n

Novo Nordisk screens as undervalued on P\/E against both its peers and its own tailored fair ratio, which points to the market pricing in a fair amount of caution already. The key question is whether that discount compensates for execution risks around manufacturing capacity, competitive pressure from Eli Lilly and potential pricing headwinds from wider access programs. What matters most from here is whether Novo Nordisk can sustain attractive returns from obesity and diabetes treatments without further margin or volume pressure. That tension between a seemingly cheap multiple and very real competitive and capacity risks is what ultimately separates the bull and bear views. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…\n","protected":false},"author":2,"featured_media":148851,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[13009,276,272],"class_list":["post-148850","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-diabetes-treatments","tag-eli-lilly","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117123522452644852","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/148850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=148850"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/148850\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/148851"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=148850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=148850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=148850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}